JP2016504420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504420A5 JP2016504420A5 JP2015553162A JP2015553162A JP2016504420A5 JP 2016504420 A5 JP2016504420 A5 JP 2016504420A5 JP 2015553162 A JP2015553162 A JP 2015553162A JP 2015553162 A JP2015553162 A JP 2015553162A JP 2016504420 A5 JP2016504420 A5 JP 2016504420A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- notch
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 5
- 238000012217 deletion Methods 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 4
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims 4
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 claims 4
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 claims 4
- 101000577163 Homo sapiens Neurogenic locus notch homolog protein 4 Proteins 0.000 claims 4
- 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 claims 4
- 101000577200 Mus musculus Neurogenic locus notch homolog protein 2 Proteins 0.000 claims 4
- 101000577203 Mus musculus Neurogenic locus notch homolog protein 3 Proteins 0.000 claims 4
- 101000577164 Mus musculus Neurogenic locus notch homolog protein 4 Proteins 0.000 claims 4
- 102000005650 Notch Receptors Human genes 0.000 claims 4
- 108010070047 Notch Receptors Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000045609 human NOTCH1 Human genes 0.000 claims 4
- 102000046883 human NOTCH2 Human genes 0.000 claims 4
- 102000047120 human NOTCH4 Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 claims 3
- 101000994434 Homo sapiens Protein jagged-2 Proteins 0.000 claims 3
- 108700041286 delta Proteins 0.000 claims 3
- 102000056036 human JAG1 Human genes 0.000 claims 3
- 102000051466 human JAG2 Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 2
- 101000994436 Mus musculus Protein jagged-1 Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 102000044446 human CD46 Human genes 0.000 claims 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100021186 Granulysin Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001040751 Homo sapiens Granulysin Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims 1
- 206010041865 Squamous cell carcinoma of the tongue Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000010029 ameloblastoma Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004293 potassium hydrogen sulphite Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1300706.7 | 2013-01-15 | ||
| GBGB1300706.7A GB201300706D0 (en) | 2013-01-15 | 2013-01-15 | Antibody |
| PCT/GB2014/050104 WO2014111704A1 (en) | 2013-01-15 | 2014-01-15 | Antibodies that bind to jagged 1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504420A JP2016504420A (ja) | 2016-02-12 |
| JP2016504420A5 true JP2016504420A5 (enExample) | 2017-04-13 |
| JP6416117B2 JP6416117B2 (ja) | 2018-10-31 |
Family
ID=47758013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553162A Expired - Fee Related JP6416117B2 (ja) | 2013-01-15 | 2014-01-15 | Ｊａｇｇｅｄ１に結合する抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9725518B2 (enExample) |
| EP (1) | EP2945968B1 (enExample) |
| JP (1) | JP6416117B2 (enExample) |
| CA (1) | CA2897869A1 (enExample) |
| DK (1) | DK2945968T3 (enExample) |
| ES (1) | ES2724244T3 (enExample) |
| GB (1) | GB201300706D0 (enExample) |
| WO (1) | WO2014111704A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6571115B2 (ja) * | 2014-02-12 | 2019-09-04 | ジェネンテック， インコーポレイテッド | 抗ｊａｇｇｅｄ１抗体及び使用方法 |
| WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
| PL234632B1 (pl) * | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
| US20190134169A1 (en) * | 2016-04-26 | 2019-05-09 | Temple University-Of The Commonwealth System Of Higher Education | DLL4-expressing cells and vaccine using the same |
| JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
| EP3438128B1 (en) * | 2017-08-04 | 2020-05-20 | Alzheimur 2012 S.L. | Anti-presenilin antibody for use in the prevention and/or treatment of cancer |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| WO2019075187A1 (en) * | 2017-10-12 | 2019-04-18 | The Trustees Of Princeton University | METHODS OF TREATING OR PREVENTING BREAST CANCER METASTASES USING ANTIBODIES AGAINST JAGGED1 AND CHEMOTHERAPEUTIC AGENTS |
| US11376307B2 (en) * | 2018-01-08 | 2022-07-05 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140826A1 (en) | 2007-05-15 | 2008-11-20 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| US8945569B2 (en) * | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
| EP2863948B1 (en) * | 2012-06-22 | 2018-10-24 | Cytomx Therapeutics Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
-
2013
- 2013-01-15 GB GBGB1300706.7A patent/GB201300706D0/en not_active Ceased
-
2014
- 2014-01-15 DK DK14701426.0T patent/DK2945968T3/da active
- 2014-01-15 ES ES14701426T patent/ES2724244T3/es active Active
- 2014-01-15 EP EP14701426.0A patent/EP2945968B1/en active Active
- 2014-01-15 CA CA2897869A patent/CA2897869A1/en not_active Abandoned
- 2014-01-15 JP JP2015553162A patent/JP6416117B2/ja not_active Expired - Fee Related
- 2014-01-15 WO PCT/GB2014/050104 patent/WO2014111704A1/en not_active Ceased
- 2014-01-15 US US14/761,062 patent/US9725518B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504420A5 (enExample) | ||
| RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
| JP2017506217A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| IL317587A (en) | Antibody against SIRPalpha | |
| JP2018070648A5 (enExample) | ||
| JP2013513383A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2020500538A5 (enExample) | ||
| RU2017110279A (ru) | Комбинированная терапия на основе нацеленных на опухоль иммуноцитокинов, содержащих вариант il-2, и антител к человеческому pd-l1 | |
| JP2018536624A5 (enExample) | ||
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| JP2011046732A5 (enExample) | ||
| JP2018531274A5 (ja) | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 | |
| JP2017507900A5 (enExample) | ||
| JP2017517506A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2016536314A5 (enExample) | ||
| JP2014531201A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2014530017A5 (enExample) | ||
| JP2019531764A5 (enExample) | ||
| RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2015509947A5 (enExample) |